RecruitingNot Applicable

Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)

United States5,000 participantsStarted 2023-12-05

Plain-language summary

This multi-center retrospective cohort study aims to investigate the real-world outcomes of chronic subdural hematoma treated with MMAE, including clinical effectiveness, recurrence rates, and safety profile.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Consecutive adult patients (18 yrs. of age or older) * Endovascular embolization of middle meningeal artery using any embolization material: PVA particles; Onyx, nBCA glue; dimethyl sulfoxide, microcoils, PVA with microcoils Exclusion Criteria: * Endovascular embolization of middle meningeal artery using any other embolization material

What they're measuring

Reaccumulation of Hematoma

Timeframe: Within 1 month post MMAE

Rescue surgical evacuation

Timeframe: Between 1-3 months post MMAE

Trial details

NCT IDNCT06181994

SponsorMontefiore Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-08

Contact for this trial

Muhammed Amir Essibayi, MD

347-908-1889 muhammedamir.essibayi@einsteinmed.edu

View on ClinicalTrials.gov More Chronic Subdural Hematoma trials